Peter M. George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter M. George has a total of 430 co-authors. Here are the top co-authors by number of shared publications:
Anand Devaraj
Royal Brompton and Harefield Hospitals, London, UK
16 shared publicationsAthol U. Wells
Royal Brompton Hospital, London, UK
8 shared publicationsMaria Kokosi
Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London, SW3 6NP, United Kingdom; Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, United Kingdom
8 shared publications- Athol Umfrey Wells
Interstitial Lung Disease Unit, Royal Brompton Hospital & Imperial College London UK
7 shared publications Christian Rennison-Jones
Brainomix, Oxford, UK
7 shared publications- Gisli Jenkins
Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK
7 shared publications
Latest Publications
- Open Access
End of rarity: the evolving burden of interstitial lung diseases in England – trends from a national population-based cohort study
Background: The disease burden from interstitial lung diseases (ILDs) is thought to be increasing globally, but there is a paucity of data on epidemiological trends in non-idiopathic pulmonary fibrosis (IPF) ILD. We calculated incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD in England from 2005 to 2022 and investigated trends over time. Methods: Using linked primary and secondary electronic healthcare records, we used three code-based algorithms to estimate incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD subtypes. We additionally stratified our results by sex, age-group and region. Poisson regression was used to investigate changes to trends over time. We used Kaplan-Meier methods to calculate median survival. Results: There were 153 975 incident cases of ILD in either primary or secondary care records. Incidence rates of all ILD, IPF and non-IPF ILD were 30% higher in 2022 compared with 2005, with rates plateauing from 2018 onwards. The prevalence of IPF and non-IPF ILD increased by 6% and 7%, respectively, over the study period. Mortality rates adjusted for age and sex in people with all ILD and non-IPF ILD were similar in 2022 compared with 2005 but in people with IPF it was 15% lower. Median survival of our overall ILD cohort was 5.4 years (IQR 1.88–13.03). Conclusions: Our population-based study highlights that ILD are no longer rare. Currently, there are 200 000 people living with ILD and 60 000 new cases are diagnosed each year. Healthcare and research funding needs to reflect this growing burden.
Open AccessEnd of rarity: the evolving burden of interstitial lung diseases in England – trends from a national population-based cohort study
Background: The disease burden from interstitial lung diseases (ILDs) is thought to be increasing globally, but there is a paucity of data on epidemiological trends in non-idiopathic pulmonary fibrosis (IPF) ILD. We calculated incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD in England from 2005 to 2022 and investigated trends over time. Methods: Using linked primary and secondary electronic healthcare records, we used three code-based algorithms to estimate incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD subtypes. We additionally stratified our results by sex, age-group and region. Poisson regression was used to investigate changes to trends over time. We used Kaplan-Meier methods to calculate median survival. Results: There were 153 975 incident cases of ILD in either primary or secondary care records. Incidence rates of all ILD, IPF and non-IPF ILD were 30% higher in 2022 compared with 2005, with rates plateauing from 2018 onwards. The prevalence of IPF and non-IPF ILD increased by 6% and 7%, respectively, over the study period. Mortality rates adjusted for age and sex in people with all ILD and non-IPF ILD were similar in 2022 compared with 2005 but in people with IPF it was 15% lower. Median survival of our overall ILD cohort was 5.4 years (IQR 1.88–13.03). Conclusions: Our population-based study highlights that ILD are no longer rare. Currently, there are 200 000 people living with ILD and 60 000 new cases are diagnosed each year. Healthcare and research funding needs to reflect this growing burden.
- Open Access
- 19 August 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003974
Automated identification of interstitial lung abnormalities in lung screening using quantitative CT
Objectives: Interstitial lung abnormalities (ILAs) are an important incidental finding in lung screening. Quantitative CT (qCT) offers a promising approach to standardising ILA assessment; however, its adoption into routine clinical practice remains limited, largely due to the need for further clinical validation. Setting: We evaluated the performance of e-Lung (Brainomix), a commercially available qCT tool in assessing ILAs for participants attending a lung cancer screening programme. Participants: All participants invited to attend the West London lung cancer screening pilot programme between 2018 and 2020. Primary outcome measures: To define the optimal qCT biomarker thresholds that identified ILA as defined by expert thoracic radiologists. Results: e-Lung qCT biomarkers had an area under the curve of between 0.82 and 0.88, and between 0.84 and 0.87 for visually quantified ILA extent thresholds of at least 5% and >10%, respectively. Conclusion: e-Lung is a qCT tool with potential utility in the automated identification of ILA in participants undergoing lung screening.
- 19 August 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003974
Open AccessAutomated identification of interstitial lung abnormalities in lung screening using quantitative CT
Objectives: Interstitial lung abnormalities (ILAs) are an important incidental finding in lung screening. Quantitative CT (qCT) offers a promising approach to standardising ILA assessment; however, its adoption into routine clinical practice remains limited, largely due to the need for further clinical validation. Setting: We evaluated the performance of e-Lung (Brainomix), a commercially available qCT tool in assessing ILAs for participants attending a lung cancer screening programme. Participants: All participants invited to attend the West London lung cancer screening pilot programme between 2018 and 2020. Primary outcome measures: To define the optimal qCT biomarker thresholds that identified ILA as defined by expert thoracic radiologists. Results: e-Lung qCT biomarkers had an area under the curve of between 0.82 and 0.88, and between 0.84 and 0.87 for visually quantified ILA extent thresholds of at least 5% and >10%, respectively. Conclusion: e-Lung is a qCT tool with potential utility in the automated identification of ILA in participants undergoing lung screening.
- Open Access
- 22 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease
Interstitial lung disease (ILD)-related pulmonary hypertension (PH) is associated with high symptom burden and reduced quality of life, and has one of the worst prognoses of all PH subgroups [1, 2]. The onset of PH in patients with ILD is insidious and progressive [3]. Diagnosis remains challenging, as confirmation and stratification require invasive right heart catheterisation (RHC), where PH is defined by a mean pulmonary artery pressure >20 mmHg, with precapillary PH also having PCWP no more than 15 mmHg and pulmonary vascular resistance (PVR) >2 Wood units (WU) [1].
- 22 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open AccessAssessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease
Interstitial lung disease (ILD)-related pulmonary hypertension (PH) is associated with high symptom burden and reduced quality of life, and has one of the worst prognoses of all PH subgroups [1, 2]. The onset of PH in patients with ILD is insidious and progressive [3]. Diagnosis remains challenging, as confirmation and stratification require invasive right heart catheterisation (RHC), where PH is defined by a mean pulmonary artery pressure >20 mmHg, with precapillary PH also having PCWP no more than 15 mmHg and pulmonary vascular resistance (PVR) >2 Wood units (WU) [1].
- 31 December 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (1) , 101359
BAL cells analysis and lung function parameters in fibrotic hypersensitivity pneumonitis at baseline and in relation to survival
- 31 December 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (1) , 101359
BAL cells analysis and lung function parameters in fibrotic hypersensitivity pneumonitis at baseline and in relation to survival
- Open Access
- 18 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
e-Lung computed tomography biomarkers are associated with outcomes in fibrotic interstitial lung diseases
Background: The e-Lung weighted reticulovascular score (WRVS) is an automated computed tomography biomarker that quantifies interstitial lung disease (ILD) severity and is associated with prognosis in patients with idiopathic pulmonary fibrosis (IPF). The aims of the present study were to evaluate WRVS as a prognostic factor in patients with non-IPF ILD. Methods: The test cohort comprised patients from the Open Source Imaging Consortium and the validation cohort, patients recruited to the prospective German CoWorker ILD registry. Associations between baseline and serial WRVS with future forced vital capacity (FVC) decline and survival were tested. Results: Median survival was 7.1 and 6.1 years in the test (n=302) and validation (n=378) cohorts, respectively. Baseline WRVS was associated with mortality in test (hazard ratio (HR) 1.11, 95% CI 1.08–1.14; p<0.001, C-index 0.75) and validation (HR 1.12, 95% CI 1.09–1.15; p<0.001, C-index 0.72) cohorts. A threshold WRVS of ≥15% was associated with mortality in both cohorts (HR 4.77, 95% CI 3.11–7.31; p<0.001, C-index 0.71, and HR 3.49, 95% CI 2.48–4.91; p<0.001, C-index 0.63 for test and validation cohorts, respectively). After adjustment for FVC, age and sex, baseline WRVS was associated with future FVC decline or death in test (OR 1.13, 95% CI 1.06–1.21; p<0.001, C-index 0.72) and validation (OR 1.18, 95% CI 1.11–1.25; p<0.001, C-index 0.72) cohorts. A rise in WRVS of 3% on serial computed tomography was associated with mortality in both test (HR 5.69, 95% CI 2.77–11.70; p<0.001, C-index 0.75) and validation cohorts (HR 1.99, 95% CI 1.09–3.65; p=0.026, C-index 0.57). Conclusion: In patients with non-IPF ILD, the e-Lung WRVS biomarker is associated with mortality and FVC decline when applied to baseline high-resolution computed tomography scans replicating previous studies in IPF. Patients with an increase in WRVS of 3% on serial computed tomography scans have significantly increased risk of mortality.
- 18 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open Accesse-Lung computed tomography biomarkers are associated with outcomes in fibrotic interstitial lung diseases
Background: The e-Lung weighted reticulovascular score (WRVS) is an automated computed tomography biomarker that quantifies interstitial lung disease (ILD) severity and is associated with prognosis in patients with idiopathic pulmonary fibrosis (IPF). The aims of the present study were to evaluate WRVS as a prognostic factor in patients with non-IPF ILD. Methods: The test cohort comprised patients from the Open Source Imaging Consortium and the validation cohort, patients recruited to the prospective German CoWorker ILD registry. Associations between baseline and serial WRVS with future forced vital capacity (FVC) decline and survival were tested. Results: Median survival was 7.1 and 6.1 years in the test (n=302) and validation (n=378) cohorts, respectively. Baseline WRVS was associated with mortality in test (hazard ratio (HR) 1.11, 95% CI 1.08–1.14; p<0.001, C-index 0.75) and validation (HR 1.12, 95% CI 1.09–1.15; p<0.001, C-index 0.72) cohorts. A threshold WRVS of ≥15% was associated with mortality in both cohorts (HR 4.77, 95% CI 3.11–7.31; p<0.001, C-index 0.71, and HR 3.49, 95% CI 2.48–4.91; p<0.001, C-index 0.63 for test and validation cohorts, respectively). After adjustment for FVC, age and sex, baseline WRVS was associated with future FVC decline or death in test (OR 1.13, 95% CI 1.06–1.21; p<0.001, C-index 0.72) and validation (OR 1.18, 95% CI 1.11–1.25; p<0.001, C-index 0.72) cohorts. A rise in WRVS of 3% on serial computed tomography was associated with mortality in both test (HR 5.69, 95% CI 2.77–11.70; p<0.001, C-index 0.75) and validation cohorts (HR 1.99, 95% CI 1.09–3.65; p=0.026, C-index 0.57). Conclusion: In patients with non-IPF ILD, the e-Lung WRVS biomarker is associated with mortality and FVC decline when applied to baseline high-resolution computed tomography scans replicating previous studies in IPF. Patients with an increase in WRVS of 3% on serial computed tomography scans have significantly increased risk of mortality.
- Open Access
- 16 October 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Survival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype
Pulmonary hypertension (PH) is common in patients with interstitial lung disease (ILD), observed in 7–15% of those with early idiopathic pulmonary fibrosis (IPF) [1] and in over 70% in those with late-stage disease [2]. PH drives an increase in mortality which appears independent of haemodynamic severity in patients with ILD-PH [3]. Historic ILD registries suggest that survival is dependent upon ILD subtype; for instance, overall survival in non-IPF subtypes, including nonspecific interstitial pneumonia (NSIP), greatly exceeds that of IPF [4].
- 16 October 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessSurvival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype
Pulmonary hypertension (PH) is common in patients with interstitial lung disease (ILD), observed in 7–15% of those with early idiopathic pulmonary fibrosis (IPF) [1] and in over 70% in those with late-stage disease [2]. PH drives an increase in mortality which appears independent of haemodynamic severity in patients with ILD-PH [3]. Historic ILD registries suggest that survival is dependent upon ILD subtype; for instance, overall survival in non-IPF subtypes, including nonspecific interstitial pneumonia (NSIP), greatly exceeds that of IPF [4].
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4556
Performance comparison of e-Lung with densitometry in the CT evaluation of patients with IPF
Introduction: e-Lung (Brainomix, Oxford) is an AI based imaging module used to assess CT scans from patients with interstitial lung disease. An e-lung derived biomarker, the reticulovascular score (RVS) quantifies reticular and vascular structures within the lungs with the weighted RVS (WRVS) assigning increased importance to the periphery. An alternative approach is to quantify densitometry with high attenuation areas (HAA) defined as % lung between -250 and -600 Hounsfield Units. Aims: To compare the performance of e-Lung derived RVS and WRVS biomarkers with HAA% in patients with idiopathic pulmonary fibrosis (IPF)(Figure 1) erj;64/suppl_68/OA4556/F1 F1 F1 Methods: Consecutive patients with IPF from the Open Source Imaging Consortium were studied. Relationships between median baseline imaging biomarkers and survival were evaluated using Cox regression with hazard ratios (HR) and 95% confidence intervals (CI) presented. Results: Of 344 patients included, 290 (84%) were male, mean age 69, mean forced vital capacity 2.8L (81%). Baseline WRVS% was most strongly associated with transplant free survival with a HR of 4.55 (3.05-6.78), p<0.001. Baseline RVS% had a HR of 3.50 (2.21-5.56), p<0.001. An analysis of the association between HAA% and transplant free survival showed a HR of 2.60 (1.27–5.32), p<0.001. Conclusions: In a diverse cohort of IPF patients, the prognostic performance of e-Lung WRVS and RVS biomarkers from a baseline CT scan outperformed HAA.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4556
Performance comparison of e-Lung with densitometry in the CT evaluation of patients with IPF
Introduction: e-Lung (Brainomix, Oxford) is an AI based imaging module used to assess CT scans from patients with interstitial lung disease. An e-lung derived biomarker, the reticulovascular score (RVS) quantifies reticular and vascular structures within the lungs with the weighted RVS (WRVS) assigning increased importance to the periphery. An alternative approach is to quantify densitometry with high attenuation areas (HAA) defined as % lung between -250 and -600 Hounsfield Units. Aims: To compare the performance of e-Lung derived RVS and WRVS biomarkers with HAA% in patients with idiopathic pulmonary fibrosis (IPF)(Figure 1) erj;64/suppl_68/OA4556/F1 F1 F1 Methods: Consecutive patients with IPF from the Open Source Imaging Consortium were studied. Relationships between median baseline imaging biomarkers and survival were evaluated using Cox regression with hazard ratios (HR) and 95% confidence intervals (CI) presented. Results: Of 344 patients included, 290 (84%) were male, mean age 69, mean forced vital capacity 2.8L (81%). Baseline WRVS% was most strongly associated with transplant free survival with a HR of 4.55 (3.05-6.78), p<0.001. Baseline RVS% had a HR of 3.50 (2.21-5.56), p<0.001. An analysis of the association between HAA% and transplant free survival showed a HR of 2.60 (1.27–5.32), p<0.001. Conclusions: In a diverse cohort of IPF patients, the prognostic performance of e-Lung WRVS and RVS biomarkers from a baseline CT scan outperformed HAA.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA3783
Performance Evaluation and Validation of e-Lung in non-IPF fibrotic ILD
Background: Brainomix 360 e-Lung, CT-based, AI powered biomarkers are associated with outcomes in IPF. Their performance in non-IPF fibrotic ILD (fILD) requires further evaluation. Aim: To evaluate e-Lung in non-IPF fILD and validate prognostic thresholds in independent cohorts. Methods: In the test cohort, consecutive patients with non-IPF fILD from the Open Source Imaging Consortium were included if they had a CT scan within 12 weeks of baseline lung function. The e-Lung weighted reticulovascular score (WRVS) biomarker was tested for associations with mortality and FVC decline with an optimal WRVS threshold defined. Analyses were validated in a cohort of patients prospectively recruited to the CoWorker fILD registry. Regression analyses, hazard ratios (HR) & 95% confidence intervals are reported. Results: The test cohort comprised 289 patients, mean age 65, f=135(45%). Adjusting for age, sex and FVC, WRVS was associated with mortality (HR 1.10,1.05-1.14, p<0.001) and trend to 10% FVC decline (HR 1.09, 0.99-1.22,p=0.089). The optimal WRVS threshold was found to be 10% and adjusting for the same covariates, was associated with mortality (HR 2.24, 1.35-3.72, p=0.002) and FVC decline (HR 3.68, 1.50-9.62, p=0.006). The validation cohort comprised 347 patients, mean age 67, f=155(45%). Adjusted WRVS was associated with mortality (HR 1.15, 1.10-1.19, p<0.001) and 10% FVC decline (HR 1.07, 1.02-1.11, p=0.002). The pre-defined 10% WRVS threshold was associated with mortality (HR 2.54, 1.70-3.81, p<0.001) and FVC decline (HR 1.60, 1.07-2.37, p=0.02). Conclusion: This 2-cohort validation study of patients with non-IPF fILD demonstrates that e-Lung can prognosticate from a baseline CT scan with potential clinical applicability.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA3783
Performance Evaluation and Validation of e-Lung in non-IPF fibrotic ILD
Background: Brainomix 360 e-Lung, CT-based, AI powered biomarkers are associated with outcomes in IPF. Their performance in non-IPF fibrotic ILD (fILD) requires further evaluation. Aim: To evaluate e-Lung in non-IPF fILD and validate prognostic thresholds in independent cohorts. Methods: In the test cohort, consecutive patients with non-IPF fILD from the Open Source Imaging Consortium were included if they had a CT scan within 12 weeks of baseline lung function. The e-Lung weighted reticulovascular score (WRVS) biomarker was tested for associations with mortality and FVC decline with an optimal WRVS threshold defined. Analyses were validated in a cohort of patients prospectively recruited to the CoWorker fILD registry. Regression analyses, hazard ratios (HR) & 95% confidence intervals are reported. Results: The test cohort comprised 289 patients, mean age 65, f=135(45%). Adjusting for age, sex and FVC, WRVS was associated with mortality (HR 1.10,1.05-1.14, p<0.001) and trend to 10% FVC decline (HR 1.09, 0.99-1.22,p=0.089). The optimal WRVS threshold was found to be 10% and adjusting for the same covariates, was associated with mortality (HR 2.24, 1.35-3.72, p=0.002) and FVC decline (HR 3.68, 1.50-9.62, p=0.006). The validation cohort comprised 347 patients, mean age 67, f=155(45%). Adjusted WRVS was associated with mortality (HR 1.15, 1.10-1.19, p<0.001) and 10% FVC decline (HR 1.07, 1.02-1.11, p=0.002). The pre-defined 10% WRVS threshold was associated with mortality (HR 2.54, 1.70-3.81, p<0.001) and FVC decline (HR 1.60, 1.07-2.37, p=0.02). Conclusion: This 2-cohort validation study of patients with non-IPF fILD demonstrates that e-Lung can prognosticate from a baseline CT scan with potential clinical applicability.
- Open Access
- 8 August 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (6)
Evaluation of e-Lung automated quantitative computed tomography biomarkers in idiopathic pulmonary fibrosis
Background: In patients with idiopathic pulmonary fibrosis (IPF) there is a need to identify biomarkers that 1) are associated with increased risk of adverse outcome and 2) can be used to monitor treatment response or identify disease progression over time. Methods: Two consecutive cohorts of patients with IPF were accessed from the Open Source Imaging Consortium database. Automated computed tomography (CT) biomarkers of disease severity incorporating fibrotic and pulmonary vascular features (the reticulovascular score and weighted reticulovascular score (WRVS)) were studied. Relationships between imaging biomarkers, lung function and survival were analysed. Results: In separate test and validation cohorts, 168 and 176 patients with IPF respectively (median survival 2.6 years) were studied. A threshold of WRVS ≥15% at baseline CT was most strongly associated with transplant-free survival (HR 3.00, 95% CI 1.47–6.10, p=0.002) when adjusted for baseline forced vital capacity (FVC) and age. In patients with 12-month follow-up CT and lung function tests (n=89) an increase in 3% of WRVS (the minimal clinically important difference) was also significantly associated with reduced survival independent of FVC, and outperformed visual evaluation of progressive fibrosis. Conclusions: WRVS is an automated CT biomarker which can identify patients with IPF at increased risk of progression and is able to reliably capture disease progression over time.
- 8 August 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (6)
Open AccessEvaluation of e-Lung automated quantitative computed tomography biomarkers in idiopathic pulmonary fibrosis
Background: In patients with idiopathic pulmonary fibrosis (IPF) there is a need to identify biomarkers that 1) are associated with increased risk of adverse outcome and 2) can be used to monitor treatment response or identify disease progression over time. Methods: Two consecutive cohorts of patients with IPF were accessed from the Open Source Imaging Consortium database. Automated computed tomography (CT) biomarkers of disease severity incorporating fibrotic and pulmonary vascular features (the reticulovascular score and weighted reticulovascular score (WRVS)) were studied. Relationships between imaging biomarkers, lung function and survival were analysed. Results: In separate test and validation cohorts, 168 and 176 patients with IPF respectively (median survival 2.6 years) were studied. A threshold of WRVS ≥15% at baseline CT was most strongly associated with transplant-free survival (HR 3.00, 95% CI 1.47–6.10, p=0.002) when adjusted for baseline forced vital capacity (FVC) and age. In patients with 12-month follow-up CT and lung function tests (n=89) an increase in 3% of WRVS (the minimal clinically important difference) was also significantly associated with reduced survival independent of FVC, and outperformed visual evaluation of progressive fibrosis. Conclusions: WRVS is an automated CT biomarker which can identify patients with IPF at increased risk of progression and is able to reliably capture disease progression over time.
- Open Access
- 1 May 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (9) , 1168-1169
e-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial
- 1 May 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (9) , 1168-1169
Open Accesse-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial